Literature DB >> 2434547

Histamine levels in bronchoalveolar lavage from patients with asthma, sarcoidosis, and idiopathic pulmonary fibrosis.

J A Rankin, M Kaliner, H Y Reynolds.   

Abstract

Bronchoalveolar lavage (BAL) has been used extensively as a research tool to elucidate immunologic events occurring in the lower respiratory tract of patients with numerous diseases and, most recently, to study patients with asthma. We assessed mast-basophiloid cell numbers and histamine levels with a sensitive histamine assay, lower limit of sensitivity, 25 pg/ml, in BAL fluid from normal individuals (n = 9) and compared these results to those obtained from patients with sarcoidosis (n = 31), idiopathic pulmonary fibrosis (IPF) (n = 8), and mild asthma (n = 7). Patients with sarcoidosis demonstrated a significant increase in total BAL mast-basophiloid cells, 9.6 +/- 4.1 X 10(4), compared to total cells in normal individuals, 0.0, p = 0.03, whereas only patients with IPF had significant elevations in BAL histamine levels, 1315 +/- 737 pg/ml, versus levels in normal individuals, 161 +/- 54 pg/ml, p = 0.002. A good correlation existed between histamine levels on an aliquot of lysed BAL cells and BAL histamine levels, R = 0.655 and p = 0.02, but not with either the total number or percent mast-basophiloid cells in BAL assessed on Wright's stained cytocentrifuge preparations. Subjects with asthma had both normal numbers of BAL mast-basophiloid cells and histamine levels. These data suggest that BAL histamine levels are easily quantified, the reason(s) for elevations in BAL histamine levels in IPF need further investigation, BAL histamine levels in subjects with asthma are not elevated in those with mild and stable disease, and lumenal mast-basophiloid cells are one major source of BAL histamine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434547     DOI: 10.1016/0091-6749(87)90158-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction.

Authors:  T B Casale; D Wood; H B Richerson; B Zehr; D Zavala; G W Hunninghake
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis.

Authors:  K A Boomars; S S Wagenaar; P G Mulder; H van Velzen-Blad; J M van den Bosch
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

Review 3.  Mast cells in airway diseases and interstitial lung disease.

Authors:  Glenn Cruse; Peter Bradding
Journal:  Eur J Pharmacol       Date:  2015-05-08       Impact factor: 4.432

Review 4.  Secondary metabolites from Inula britannica L. and their biological activities.

Authors:  Abdul Latif Khan; Javid Hussain; Muhammad Hamayun; Syed Abdullah Gilani; Shabir Ahmad; Gauhar Rehman; Yoon-Ha Kim; Sang-Mo Kang; In-Jung Lee
Journal:  Molecules       Date:  2010-03-10       Impact factor: 4.411

5.  Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.

Authors:  Catherine Overed-Sayer; Elena Miranda; Rebecca Dunmore; Elena Liarte Marin; Lorea Beloki; Doris Rassl; Helen Parfrey; Alan Carruthers; Amina Chahboub; Sofia Koch; Gülin Güler-Gane; Michael Kuziora; Arthur Lewis; Lynne Murray; Richard May; Deborah Clarke
Journal:  Thorax       Date:  2020-07-24       Impact factor: 9.139

Review 6.  Are mast cells instrumental for fibrotic diseases?

Authors:  Catherine Overed-Sayer; Laura Rapley; Tomas Mustelin; Deborah L Clarke
Journal:  Front Pharmacol       Date:  2014-01-21       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.